Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
  1. Home
  2. Products
  3. Antibodies
  4. Primary Antibodies
  5. All Primary Antibodies
  6. BUV395 Biosimilar Anti-Human CD20 Rituximab297, BD Horizon™

BUV395 Biosimilar Anti-Human CD20 Rituximab297, BD Horizon™

Catalog No. BDB570360 Shop All BD Biosciences Products
Change view
Click to view available options
Quantity:
100 Tests
1 product options available for selection
Product selection table with 1 available options. Use arrow keys to navigate and Enter or Space to select.
Catalog No. Quantity
BDB570360 100 Tests
Use arrow keys to navigate between rows. Press Enter or Space to select a product option. 1 options available.
1 options
Catalog No. BDB570360 Supplier BD Biosciences Supplier No. 570360
Only null left
Add to Cart
Add to Cart

Description

Biosimilar Monoclonal Antibody

CD20 Rituximab297 Monoclonal antibody specifically detects CD20 Rituximab297 in Human samples. It is validated for Flow cytometry
TRUSTED_SUSTAINABILITY

Specifications

Antigen CD20 Rituximab297
Applications Flow Cytometry
Classification Monoclonal
Clone Rituximab297.rMAb (also known as Rituximab N297A Biosimilar.rMAb)
Conjugate Brilliant Ultraviolet 395
Formulation Aqueous buffered solution containing ≤0.09% sodium azide.
Gene Alias B1; Bp35; LEU-16; MS4A1
Host Species Mouse
Immunogen Human CD20
Purification Method Affinity Chromatography
Quantity 100 Tests
Regulatory Status RUO
Gene ID (Entrez) 931
Target Species Human
Content And Storage Store undiluted at 4°C and protected from prolonged exposure to light. Do not freeze.
Form Liquid
Isotype IgG1 κ
Show More Show Less
Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.